,

Rev Esp Quimioter 2021; May 19

Clinical characteristics and outcomes of 1,331 patients with COVID-19: HM Spanish Cohort

PABLO CARDINAL-FERNÁNDEZ, ESTEBAN GARCIA CUESTA, JOSÉ BARBERÁN, JOSÉ F. VARONA, ALBERTO ESTIRADO, ALBERTO MORENO, JULIO VILLANUEVA, MERCEDES VILLAREAL, ORVILLE BAEZ-PRAVIA, JUSTO MENÉNDEZ, PAULA VILLARES, ALEJANDRO LÓPEZ ESCOBAR, JESÚS RODRÍGUEZ-PASCUAL, CRISTINA ALMIRALL, EDUARDO DOMÍNGUEZ, CARLOS PEY, ANTONIO FERREIRO, MANUEL REVILLA AMORES, NIKE SÁNCHEZ, SANTIAGO RUIZ DE AGUIAR, JOSÉ M. CASTELLANO

Published: 19 May 2021

http://www.doi.org/10.37201/req/050.2021

Background. Spain is one of the European countries most affected by the COVID-19 pandemic. Epidemiologic studies are warranted to improve the disease understanding, evaluate the care procedure and prepare for futures waves. The aim of the study was to describe epidemiologic characteristics associated with hospitalized patients with COVID-19.
Methods. This real-world, observational, multicenter and retrospective study screened all consecutive patients admitted to 8 Spanish private hospitals. Inclusion criteria: hospitalized adults (age≥18 years old) with clinically and radiologically findings compatible with COVID-19 disease from March 1st to April 5th, 2020. Exclusion criteria: patients presenting negative PCR for SARS-CoV-2 during the first 7 days from hospital admission, transfer to a hospital not belonging to the HM consortium, lack of data and discharge against medical advice in
emergency departments.
Results. One thousand and three hundred thirty-one COVID-19 patients (medium age 66.9 years old; males n= 841, medium length of hospital stayed 8 days, non-survivors n=233) were analyzed. One hundred and fifteen were admitted to intensive care unit (medium length of stay 16 days, invasive mechanical ventilation n= 95, septic shock n= 37 and renal replacement therapy n= 17). Age, male gender, leukocytes, platelets, oxygen saturation, chronic therapy with steroids and treatment with hydroxychloroquine/azithromycin were independent factors associated with mortality. The proportion of patients that survive and received tocilizumab and steroids were lesser and higher respectively than those that die, but their association was not significant.
Conclusions. Overall crude mortality rate was 17.5%, rising up to 36.5% in the subgroup of patients that were admitted to the intensive care unit. Seven factors impact in hospital mortality. No immunomodulatory intervention were associated with in-hospital mortality.

Rev Esp Quimioter 2021; May 19 [Full-text PDF] [Supplementary material PDF]